Company news
MBX Biosciences, Inc. news in 2026
MBX Biosciences, Inc.'s news releases, calls and decks from 2026, newest first.
MBX Biosciences Reports Third Quarter 2026 Financial Results and Corporate Highlights
November 9, 2026
MBX Biosciences to Participate in Upcoming November Investor Conferences
October 13, 2026
MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer
September 8, 2026
MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism
August 27, 2026
MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights
August 6, 2026
MBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of Growth
July 13, 2026
MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism
June 12, 2026
MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026
June 1, 2026
MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City
May 26, 2026
MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing
May 10, 2026
MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award
May 7, 2026
MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio
April 23, 2026
MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 2, 2026
MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights
March 12, 2026
MBX Biosciences Appoints Karen Basbaum as Chief Business Officer
March 9, 2026
MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
March 8, 2026
CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
March 8, 2026
MBX Biosciences to Participate in Upcoming March Investor Conferences
February 22, 2026
MBX Biosciences to Participate in Upcoming Investor Conferences
February 11, 2026
MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair
January 21, 2026
MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference
January 10, 2026
Decks in 2026
- Investor Presentation (November 2026)
Investor deck · 26 slides · Nov 9, 2026
- Investor Presentation (August 2026)
Investor deck · 26 slides · Aug 6, 2026
- ENDO 2026
Conference · 37 slides · Jun 12, 2026
- Investor Day (May 2026)
Investor day · 38 slides · May 11, 2026